Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Additional FDA funds

This article was originally published in The Tan Sheet

Executive Summary

FDA receives $150 million in additional funding for fiscal 2008 in the Supplemental Appropriations Bill of 2008, H.R. 2642, signed June 30 by President Bush. The appropriation includes $66.8 million for the Center for Food Safety and Applied Nutrition, $28 million for the Center for Drug Evaluation and Research and $12.7 million for the Center of Biologics Evaluation and Research. In an effort led by Pennsylvania Republican Arlen Specter, the Senate initially approved giving FDA $275 million in additional fiscal 2008 funding, including $125 million for food protection, but the administration vowed to veto those elevated spending levels (1"The Tan Sheet" May 26, 2008, In Brief). Meantime, House appropriators look for progress on fiscal 2009 appropriations despite partisan differences (see story, p. 9)...

Latest Headlines
See All
UsernamePublicRestriction

Register

PS101835

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel